Extensive Disease Small Cell Lung Cancer, Non-small Cell Lung Cancer
Conditions
Keywords
Atezolizumab
Brief summary
This is a multi-center observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer(NSCLC) or extensive disease small cell lung cancer(ED-SCLC). 800 patients in NSCLC cohort and 400 patients in ED-SCLC cohort will be enrolled in this trial to assess the efficacy and safety of this combination.
Detailed description
Primary endpoint: 12 months OS, Secondary endpoints: Overall Survival(OS), 6 months survival rate(6mo OS), 12 months survival rate(12mo OS), Progression-Free Survival(PFS), Time to treatment failure (TTF), Objective Response Rate(ORR), Disease Control Rate(DCR), Duration of Response(DOR) ,Safety and Comprehensive geriatric assessment(G8)
Interventions
None listed
Sponsors
Japan Lung Cancer Society
Chugai Pharmaceutical
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Inclusion criteria
\< non-small cell lung cancer cohort\> 1. Patients 20 years of age or older at the time of signed consent. 2. Patients with unresectable, advanced and recurrent non-small cell lung cancer. 3. Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Use Promotion Guideline. 4. Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments. \<extensive disease small cell lung cancer cohort\> 1. Patients 20 years of age or older at the time of signed consent. 2. Patients with extensive disease small cell lung cancer. 3. Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Use Promotion Guideline. 4. Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments.
Exclusion criteria
\< non-small cell lung cancer cohort\> (1) Patients who are unsuitable for enrolment into the study by the investigator's judgment. \<extensive disease small cell lung cancer cohort\> (1) Patients who are unsuitable for enrolment into the study by the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 12 months survival rate | Baseline up to 12 Months | Percentage of participants alive 12 months after initiation of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6 moths survival rate | Up to 6 months | Percentage of participants alive 6 months after initiation of treatment |
| 18 moths survival rate | Up to 18 months | Percentage of participants alive 18 months after initiation of treatment |
| Progression-Free Survival(PFS) | Up to disease progression or death whichever occurs first (up to 3 years) | PFS based on disease status as evaluated by the investigator in accordance with Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (v1.1) |
| Time to treatment failure (TTF) | Up to 3 years | TTF was defined as the time from the first day of study treatment to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death |
| Post-treatment transfer rate | Up to post-treatment is started (up to 3 years) | Rate of patients who received drug therapy for primary disease after study treatment |
| Overall Survival | Up to death (up to 3 years) | OS was defined as the time from the first day of study treatment to death due to any cause |
| Duration of Response(DOR) | From date of first objective response up to disease progression or death whichever occurs first (up to 3 years) | Duration of Response as Assessed by the Investigator According to RECIST v1.1 |
| Disease Control Rate(DCR) | Up to 3 years | Percentage of patients with controled disease as Assessed by the investigator according to RECIST v1.1 |
| Percentage of Participants with adverse events(Adverse Reactions) | Up to 3 years | The incidence of worst-grade adverse events on study as graded by NCI-CTCAE v5.0 |
| Comprehensive geriatric assessment (G8) | At baseline | The G-8 screening tool was developed to identify elderly cancer patients who would benefit from comprehensive geriatric assessment |
| Objective Response Rate(ORR) | Up to disease progression or death whichever occurs first (up to 3 years) | Percentage of participants with objective response as assessed by the investigator according to RECIST v1.1 |
Countries
Japan
Outcome results
None listed